比美吉珠单抗治疗中轴型脊柱关节炎104周外周表现持续缓解
BE MOBILE 1(非放射学中轴型脊柱关节炎)与BE MOBILE 2(放射学中轴型脊柱关节炎)III期研究显示,比美吉珠单抗(BKZ)治疗至第104周时,附着点炎与周围关节炎持续改善;第104周超过40%的患者附着点炎消退(MASES=0),超过60%的患者关节炎消退(SJC=0)。
要点
- 合并BKZ/安慰剂随机治疗者平均MASES由基线4.8/4.3降至第104周1.6/1.0(nr-axSpA/r-axSpA)。
- 合并BKZ/安慰剂随机治疗者平均SJC由基线4.0/4.5降至第104周0.9/0.6(nr-axSpA/r-axSpA)。
- 第104周超过40%患者附着点炎消退、超过60%患者关节炎消退。
核心结论
- BKZ使中轴型脊柱关节炎全疾病谱患者的外周表现持续改善至2年。
研究设计与样本
- BE MOBILE 1(nr-axSpA)与BE MOBILE 2(r-axSpA)III期研究:先16周双盲安慰剂对照,随后全部接受BKZ 160 mg每4周一次共36周,未达退出标准者可进入合并开放标签延伸期。
- 分析基线MASES>0者的附着点炎变化、基线SJC>0者的周围关节炎(SJC/DAPSA)变化及至第104周达到DAPSA疾病状态的比例。
- 报告基线有附着点炎/关节炎者至第104周的附着点炎消退(MASES=0)/关节炎消退(SJC=0),以及外周表现消退与第104周临床结局的关联。
主要发现
- 基线时nr-axSpA患者中186/254(73.2%)有附着点炎(MASES>0)、88/254(34.6%)有关节炎(SJC>0);r-axSpA患者中分别为199/332(59.9%)和66/332(19.9%)。
- 合并BKZ/安慰剂随机治疗的附着点炎患者(nr-axSpA/r-axSpA)平均MASES由基线4.8/4.3降至第52周1.6/1.3、第104周1.6/1.0。
- 合并BKZ/安慰剂随机治疗的关节炎患者平均SJC由基线4.0/4.5降至第52周1.2/0.7、第104周0.9/0.6。
- 超过60%的患者在第52周达到DAPSA低疾病活动度/缓解。
- 第104周超过40%/60%的患者分别达到附着点炎消退(MASES=0)/关节炎消退(SJC=0);r-axSpA患者中附着点炎消退与第104周临床结局更大改善相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies. OBJECTIVE: Assess the impact of BKZ on peripheral manifestations to week 104 of those studies. METHODS: BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) each comprised a 16-week double-blind, placebo-controlled period, then all received BKZ 160 mg every 4 weeks for 36 weeks. Patients not meeting withdrawal criteria could enter a combined open-label extension. We report change in enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)) in patients with baseline MASES>0, peripheral arthritis (swollen joint count (SJC)/Disease Activity Index for Psoriatic Arthritis (DAPSA)) in patients with baseline SJC>0 and proportions achieving DAPSA disease states to week 104. Resolution of enthesitis (MASES=0)/arthritis (SJC=0) is reported to week 104 for those with baseline enthesitis/arthritis. We also report associations between peripheral manifestation resolution (MASES=0/SJC=0) and week 104 clinical outcomes in those with baseline enthesitis/arthritis. RESULTS: At baseline, 186/254 (73.2%) and 88/254 (34.6%) patients with nr-axSpA had enthesitis (MASES>0) and arthritis (SJC>0), respectively, compared with 199/332 (59.9%) and 66/332 (19.9%) patients with r-axSpA. Pooled BKZ/placebo-randomised patients with enthesitis (nr-axSpA/r-axSpA) showed average MASES improvement from 4.8/4.3 (baseline) to 1.6/1.3 (week 52) and 1.6/1.0 (week 104). Pooled BKZ/placebo-randomised patients with arthritis showed average SJC improvement from 4.0/4.5 (baseline) to 1.2/0.7 (week 52) and 0.9/0.6 (week 104). Over 60% of patients achieved DAPSA low disease activity/remission by week 52. Over 40%/60% patients achieved resolution of enthesitis (MASES=0)/arthritis (SJC=0) at week 104; enthesitis resolution was associated with larger improvements in week 104 clinical outcomes for patients with r-axSpA. CONCLUSION: BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.
引用
- Ramiro S, Poddubnyy D, Mease PJ, et al. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025. PMID: 41125403. doi:10.1136/rmdopen-2025-005969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。